SelectMDx is a National Comprehensive Cancer Network (NCCN) approved biomarker that was designed for patients who have an abnormal PSA and/or DRE who are being considered for a prostate biopsy.
Unlike PSA, which is a measurement that is specific to the prostate but not necessarily prostate cancer, SelectMDx has been shown in research to more accurately assess an individual's risk of having prostate cancer, and more specifically, clinically significant prostate cancer (greater than or equal to Gleason 7).
This is done by simply collecting a sample of urine after a digital rectal examination (physical examination of ones prostate by their health care provider). There are two types of sample reports listed below, the first result being a positive test and the second result being a negative test.
Positive Test Result
Below you will find an example of a positive test result. Simply hover your cursor over key areas of the report to learn what each section means.
Negative Test Result
Below you will find an example of a negative test result. Simply hover your cursor over key areas of the report to learn what each section means.
There are many factors that contribute to the decision to have a prostate biopsy. It is very important to have an in depth discussion with your physician to decide which option is right for your particular scenario and allow them to guide you through an appropriate diagnostic plan. This report does not rule out the presence of a low grade prostate cancer, such as a Gleason 3+3=6.